Maverix Biomics, a San Mateo-based software company that does sequencing genomic data analysis, announced yesterday it closed a $6 million Series A funding round.
The financing was led by the venture capital firm Asset Management Ventures and two prominent Silicon Valley information technology investors, Andreas Bechtolsheim and Andrew Yang.
Maverix’s pioneering flagship offering, the Maverix Analytic Platform, simplifies complex big data analytics for life science researchers, integrating context-based data exploration, interactive visualization, secure data management and affordable long-term storage in an easy-to-use cloud-based solution.
“Maverix is a great example of a portfolio company where Asset Management can offer its expertise in both life sciences and information technology,” Louis G. Lange, general partner at Asset Management Ventures, said in a press release. “We have been consistently impressed with the company’s leadership, scientific and software development expertise. As high-throughput sequencing becomes a mainstream research and clinical technology, bioinformatics must move from the computer room directly into the hands of life scientists, creating a hundred-fold increase in potential customers that Maverix is uniquely poised to serve.”
Researchers using the Maverix platform experience a simple, collaborative user environment that allows them to upload their own data, initiate their own analyses and put their results in context with other public and private data sources, according to the release.
Leveraging the power of open source analytic tools that previously have been available only to bioinformatics experts, researchers are able to immediately perform analyses with reliable, scientifically recommended configurations, as validated and cited in peer-reviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including the University of California at Santa Cruz Genome Browser, the world’s most widely used genome browser, according to the release.